Unraveling the Epigenetic Landscape of Mature B Cell Neoplasia: Mechanisms, Biomarkers, and Therapeutic Opportunities
International Journal of Molecular Sciences · 22.08.2025 · 26 (17) · 8132
DOI: 10.3390/ijms26178132 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 22.08.2025. Verfasst von Nawar Maher und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale and Azienda Ospedaliero-Universitaria di Alessandria,…. Hauptthemen laut MEDLINE: Epigenesis, Genetic, Biomarkers, Tumor, Lymphoma, Large B-Cell, Diffuse, Leukemia, Lymphocytic, Chronic, B-Cell. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 157 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Molecular bases of disease dissemination in lymphoid malignancies to optimize curative therapeutic strategies, the AGING Project - Department of Excellence - DIMET, Università del Piemonte Orientale, Novara, Italy, PNRR-MAD-2022-12375673 (Next Generation EU, M6/C2_CALL 2022).
Abstract (Originalsprache)
Epigenetic regulation is critical to B cell development, guiding gene expression via DNA methylation, histone modifications, chromatin remodeling, and noncoding RNAs. In mature B cell neoplasms, particularly diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL), these mechanisms are frequently disrupted. Recurrent mutations in key epigenetic regulators such as EZH2, KMT2D, CREBBP, and TET2 lead to altered chromatin states, repression of tumor suppressor genes, and enhanced oncogenic signaling. Dysregulation of specific microRNAs (e.g., miR-155, miR-21) further contributes to pathogenesis and therapeutic resistance. In DLBCL, hypermethylation of SMAD1 and CREBBP mutations are associated with immune evasion and chemoresistance. In FL, EZH2 gain-of-function and KMT2D loss-of-function mutations alter germinal center B cell programming, while in CLL, DNA hypomethylation patterns reflect the cell of origin and correlate with clinical outcome. Targeted therapies such as the EZH2 inhibitor tazemetostat have demonstrated efficacy in EZH2-mutant FL, while HDAC and BET inhibitors show variable responses across B cell malignancies. The limitations of current epigenetic therapies reflect the complexity of targeting epigenetic dysregulation rather than therapeutic futility. These challenges nonetheless highlight the relevance of epigenetic alterations as biomarkers and therapeutic targets, with potential to improve the management of mature B cell neoplasms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale and Azienda Ospedaliero-Universitaria di Alessandria, 15121 Alessandria, Italy.
- Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale and Azienda Ospedaliero-Universitaria Maggiore della Carità, 28100 Novara, Italy.
ORCID-Profile: Nawar Maher, Francesca Maiellaro, Joseph Ghanej, Gianluca Gaidano
Förderung
- Molecular bases of disease dissemination in lymphoid malignancies to optimize curative therapeutic strategies
- the AGING Project - Department of Excellence - DIMET, Università del Piemonte Orientale, Novara, Italy
- PNRR-MAD-2022-12375673 (Next Generation EU, M6/C2_CALL 2022)
- Italian MoH, Rome, Italy
- AIL Novara VCO ODV, Novara, Italy
- AGING Project—Department of Excellence—DIMET, Università del Piemonte Orientale, Novara, Italy
- Next Generation EU
Zitieren
APA
Maher, N., Maiellaro, F., Ghanej, J., Rasi, S., Moia, R., & Gaidano, G. (2025). Unraveling the Epigenetic Landscape of Mature B Cell Neoplasia: Mechanisms, Biomarkers, and Therapeutic Opportunities. International Journal of Molecular Sciences, 26(17), 8132. https://doi.org/10.3390/ijms26178132
Vancouver
Maher N, Maiellaro F, Ghanej J, Rasi S, Moia R, Gaidano G. Unraveling the Epigenetic Landscape of Mature B Cell Neoplasia: Mechanisms, Biomarkers, and Therapeutic Opportunities. International Journal of Molecular Sciences. 2025;26(17):8132. doi:10.3390/ijms26178132
BibTeX
@article{Maher2025,
author = {Maher, Nawar and Maiellaro, Francesca and Ghanej, Joseph and Rasi, Silvia and Moia, Riccardo and Gaidano, Gianluca},
title = {Unraveling the Epigenetic Landscape of Mature B Cell Neoplasia: Mechanisms, Biomarkers, and Therapeutic Opportunities},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {17},
pages = {8132},
doi = {10.3390/ijms26178132}
}
EUVIMED